Articles
-
Alzheimer’s Drug Approved; USC Policy Experts Available to Discuss FDA Approval of Leqembi
For the first time in two decades, an Alzheimer’s drug has received full Food and Drug Administration (FDA) approval. USC Schaeffer Center experts are available to discuss this milestone and the challenges ahead.
Categorized in -
Health Care Privacy Risks of AI Chatbots
Ultimately, health systems facing increased risk of AI chatbot breaches must decide whether to discourage clinicians’ use of this technology or embrace it.
Categorized in -
Without Early Detection, Fighting Dementia Is an Uphill Battle
A brief assessment in primary care can help identify patients most at risk
Categorized in -
Favorable Selection Ups the Ante on Medicare Advantage Payment Reform
Overpayment to Medicare Advantage plans due to favorable selection, “coding intensity” and rating bonuses could exceed $75B in 2023.
Categorized in -
Overpayments to Medicare Advantage Plans Could Exceed $75 Billion in 2023, USC Schaeffer Center Research Finds
Overpayments to Medicare Advantage plans now exceed 20% annually, underscoring the urgent need for reform.
Categorized in -
Comparing Doctors to Peers Doesn’t Make Them Hate Their Jobs and May Improve Quality of Care
Researchers found that behavioral interventions aimed at improving performance can be designed to protect clinician job satisfaction and improve quality of care.
Categorized in -
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Categorized in -
Four Ways to Make Drug Price Negotiations Work for Everyone
The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
Categorized in -
COVID-19’s Total Cost to the U.S. Economy Will Reach $14 Trillion by End of 2023
Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.
Categorized in -
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Categorized in